Literature DB >> 30578845

A lentivirus-based system for Cas9/gRNA expression and subsequent removal by Cre-mediated recombination.

Michael A Carpenter1, Emily K Law2, Artur Serebrenik3, William L Brown4, Reuben S Harris5.   

Abstract

A major concern of CRISPR and related genome engineering technologies is off-target mutagenesis from prolonged exposure to Cas9 and related editing enzymes. To help mitigate this concern we added a loxP site to the 3'-LTR of an HIV-based lentiviral vector capable of expressing Cas9/gRNA complexes in a wide variety of mammalian cell types. Transduction of susceptible target cells yields an integrated provirus that expresses the desired Cas9/gRNA complex. The reverse transcription process also results in duplication of the 3'-LTR such that the integrated provirus becomes flanked by loxP sites (floxed). Subsequent expression of Cre recombinase results in loxP-to-loxP site-specific recombination that deletes the Cas9/gRNA payload and effectively prevents additional Cas9-mediated mutations. This construct also expresses a gRNA with a single transcription termination sequence, which results in higher expression levels and more efficient genome engineering as evidenced by disruption of the SAMHD1 gene. This hit-and-run CRISPR approach was validated by recreating a natural APOBEC3B deletion and by disrupting the mismatch repair gene MSH2. This hit-and-run strategy may have broad utility in many areas and especially those where cell types are difficult to engineer by transient delivery of ribonucleoprotein complexes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; Cas9; Cre recombinase; gRNA; loxP; pLentiCRISPR1000

Mesh:

Substances:

Year:  2018        PMID: 30578845      PMCID: PMC6397784          DOI: 10.1016/j.ymeth.2018.12.006

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  36 in total

1.  Role of nucleotide sequences of loxP spacer region in Cre-mediated recombination.

Authors:  G Lee; I Saito
Journal:  Gene       Date:  1998-08-17       Impact factor: 3.688

Review 2.  A decade of discovery: CRISPR functions and applications.

Authors:  Rodolphe Barrangou; Philippe Horvath
Journal:  Nat Microbiol       Date:  2017-06-05       Impact factor: 17.745

3.  High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells.

Authors:  Yanfang Fu; Jennifer A Foden; Cyd Khayter; Morgan L Maeder; Deepak Reyon; J Keith Joung; Jeffry D Sander
Journal:  Nat Biotechnol       Date:  2013-06-23       Impact factor: 54.908

4.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.

Authors:  Prashant Mali; John Aach; P Benjamin Stranges; Kevin M Esvelt; Mark Moosburner; Sriram Kosuri; Luhan Yang; George M Church
Journal:  Nat Biotechnol       Date:  2013-08-01       Impact factor: 54.908

Review 5.  CRISPR-Cas guides the future of genetic engineering.

Authors:  Gavin J Knott; Jennifer A Doudna
Journal:  Science       Date:  2018-08-31       Impact factor: 47.728

6.  Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system.

Authors:  Baohui Chen; Luke A Gilbert; Beth A Cimini; Joerg Schnitzbauer; Wei Zhang; Gene-Wei Li; Jason Park; Elizabeth H Blackburn; Jonathan S Weissman; Lei S Qi; Bo Huang
Journal:  Cell       Date:  2013-12-19       Impact factor: 41.582

7.  High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity.

Authors:  Vikram Pattanayak; Steven Lin; John P Guilinger; Enbo Ma; Jennifer A Doudna; David R Liu
Journal:  Nat Biotechnol       Date:  2013-08-11       Impact factor: 54.908

8.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

9.  Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.

Authors:  Johnny H Hu; Shannon M Miller; Maarten H Geurts; Weixin Tang; Liwei Chen; Ning Sun; Christina M Zeina; Xue Gao; Holly A Rees; Zhi Lin; David R Liu
Journal:  Nature       Date:  2018-02-28       Impact factor: 49.962

Review 10.  Off-target Effects in CRISPR/Cas9-mediated Genome Engineering.

Authors:  Xiao-Hui Zhang; Louis Y Tee; Xiao-Gang Wang; Qun-Shan Huang; Shi-Hua Yang
Journal:  Mol Ther Nucleic Acids       Date:  2015-11-17       Impact factor: 10.183

View more
  7 in total

1.  The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase.

Authors:  Artur A Serebrenik; Gabriel J Starrett; Sterre Leenen; Matthew C Jarvis; Nadine M Shaban; Daniel J Salamango; Hilde Nilsen; William L Brown; Reuben S Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.

Authors:  Jennifer L McCann; Madeline M Klein; Evelyn M Leland; Emily K Law; William L Brown; Daniel J Salamango; Reuben S Harris
Journal:  J Biol Chem       Date:  2019-06-19       Impact factor: 5.157

3.  The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.

Authors:  Artur A Serebrenik; Prokopios P Argyris; Matthew C Jarvis; William L Brown; Martina Bazzaro; Rachel I Vogel; Britt K Erickson; Sun-Hee Lee; Krista M Goergen; Matthew J Maurer; Ethan P Heinzen; Ann L Oberg; Yajue Huang; Xiaonan Hou; S John Weroha; Scott H Kaufmann; Reuben S Harris
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

4.  Small Molecule Inhibitors of Activation-Induced Deaminase Decrease Class Switch Recombination in B Cells.

Authors:  Juan Alvarez-Gonzalez; Adam Yasgar; Robert W Maul; Amanda E Rieffer; Daniel J Crawford; Daniel J Salamango; Dorjbal Dorjsuren; Alexey V Zakharov; Daniel J Jansen; Ganesha Rai; Juan Marugan; Anton Simeonov; Reuben S Harris; Rahul M Kohli; Patricia J Gearhart
Journal:  ACS Pharmacol Transl Sci       Date:  2021-05-07

5.  A Rabbit Monoclonal Antibody against the Antiviral and Cancer Genomic DNA Mutating Enzyme APOBEC3B.

Authors:  William L Brown; Emily K Law; Prokopios P Argyris; Michael A Carpenter; Rena Levin-Klein; Alison N Ranum; Amy M Molan; Colleen L Forster; Brett D Anderson; Lela Lackey; Reuben S Harris
Journal:  Antibodies (Basel)       Date:  2019-09-10

6.  MagnEdit-interacting factors that recruit DNA-editing enzymes to single base targets.

Authors:  Jennifer L McCann; Daniel J Salamango; Emily K Law; William L Brown; Reuben S Harris
Journal:  Life Sci Alliance       Date:  2020-02-24

7.  Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B.

Authors:  Chai Yeen Goh; Boon Haow Chua; Pieter A Roelofs; Matthew C Jarvis; Teneale A Stewart; Jennifer L McCann; Rebecca M McDougle; Michael A Carpenter; John Wm Martens; Paul N Span; Dennis Kappei; Reuben S Harris
Journal:  Elife       Date:  2020-09-28       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.